Document is current
Any future updates will be listed below
-
Authors
Leingang, Oliver
Riedl, Sophie
Mai, Julia
Reiter, Gregor S.
Faustmann, Georg
Fuchs, Philipp
Scholl, Hendrik P. N.
Sivaprasad, Sobha
Rueckert, Daniel
Lotery, Andrew
Schmidt-Erfurth, Ursula
Bogunović, Hrvoje
-
Funding
Funding for this research was provided by:
Wellcome Trust (10572/Z/18/Z.)
Wellcome Trust (10572/Z/18/Z.)
Wellcome Trust (10572/Z/18/Z.)
Wellcome Trust (10572/Z/18/Z.)
Wellcome Trust (10572/Z/18/Z.)
Wellcome Trust (10572/Z/18/Z.)
Wellcome Trust (10572/Z/18/Z.)
Wellcome Trust (10572/Z/18/Z.)
- License Information
-
More Information
Article History
Received: 8 August 2023
Accepted: 3 November 2023
First Online: 9 November 2023
Competing interests
: G.S.R.: RetInSight: Grant funding. H.B.: Contract Research to the Medical University of Vienna: Apellis, Heidelberg Engineering. U.S-E: Scientific Consultant: Genentech, Heidelberg, Kodiak, Novartis, RetInSight, Roche, Contract Research to the Medical University of Vienna: Apellis, Genentech, Kodiak. A.J.L.: Support: Roche, Scientific Consultant - Roche, Eyebio, Participation: Apellis, Stocks: Gyroscope Therapeutics. D.R.: Grant: EU Commision, Innovate UK, German Federal Ministry of Education and Research, Engineering and Physical Sciences Research Council, German Research Foundation, Consultant: HeartFlow, IXICO. S.S.: Grants - Boehringer Ingelheim, Bayer, AbbVie, Optos; Consultant - Bayer, Novartis, Biogen, Roche, Apellis, Eyebiotech, Boehringer Ingelheim; Payment - Bayer, Roche, Boehringer Ingelheim, AbbVie; Support - Bayer, Roche; Participation - Bayer; Leadership - Macular Society Trustee, Trustee of the Royal College of Ophthalmologists. H.P.N.S.: Grant - the Swiss National Science Foundation, National Center of Competence in Research Molecular Systems Engineering, Foundation Fighting Blindness Clinical Research Institute; Consultant - Boehringer Ingelheim, Claris Biotherapeutics Inc, Eluminex Biosciences, Gyroscope Therapeutics Ltd, Janssen Research & Development, LLC (Johnson & Johnson), Okuvision GmbH, ReVision Therapeutics Inc, Saliogen Therapeutics Inc, Alnylam Pharmaceuticals Inc, Gerson Lehrman Group Inc, Guidepoint Global, LLC, Intergalactic Therapeutics Inc; Patents - Methods to assess cone availability in patients with vision impairments, Human Cone Photoreceptor Optogenetic Constructs, Promoter for specific expression of genes in rod photoreceptors; Participation - Belite Bio, Roche, Novo Nordisk. Other remaining authors have no competing interests to declare.
